From Lyme Vaccines to Match Day: Why Integration is Our Greatest Hurdle

March 31, 2026‍ ‍

The final week of March always brings a sense of renewal, but in population health, it also brings a sobering look at our structural foundations. This week, we saw a record-breaking "Match Day" for new doctors, but the celebration was tempered by a widening gap in one area, primary care. Which is one of the pillars of Population Health, along with data, clinical and non-clinical interventions, and engagement, that when integrated are the key to improving health. We saw a “potential win" in the fight against Lyme disease, but a new study of midwives in the Canadian Health system reminds us that high-trust care models still face an uphill battle with public health integration, often taking one step forward and one step back.

As we add more Players, Processes, Payments, and dare I say Population AInalytics (sp), will we ever truly integrate our system?

Here is your briefing and some quick thoughts on the four stories defining the final week of March.

1. Match Day 2026: A Record with a Warning Label‍ ‍

Last week, a record 44,344 residency positions were filled, the largest in history. On the surface, it’s a "step forward" for the future workforce. However, the data reveal a persistent "step back": while more primary care and family medicine slots were filled, a record number went unfilled in the initial match compared to 2025. As we pivot to value-based care, our "engine room”: primary care, is still facing a recruitment crisis that could bottleneck chronic disease management and population health for decades. Primary care from the healthcare side, combined with community engagement and interventions targeting those areas outside the healthcare system that drive our poor health statistics are the key to making major strides in improving our overall health status in the United States. Can we flip the payment model to reward those we need the most?‍ ‍

Source:NRMP 2026 Main Residency Match Data‍ ‍

2. The Lyme Vaccine: A 70% Win for Prevention.

After years of rising tick-borne illness cases, Pfizer and Valneva announced this week that their Phase 3 trial for a Lyme disease vaccine showed 70% efficacy in preventing symptomatic infection. But there were some issues as their primary endpoint was not met. As climate change expands tick habitats, this could be a preventive health strategy for millions of at-risk Americans. But until then, whenever I’m hiking or backpacking, it’s permethrin on the clothes and a bug spray with DEET.  Followed by a tick check at the end of the day. Use DEET sparingly and per the CDC, not on children under 2 months of age.

Source:Pfizer and Valneva Announce Positive Phase 3 Results for Lyme Disease Vaccine Candidate‍ ‍

3. Midwife-Led Care: The Trust-Vaccination Paradox

This one’s a bit frustrating.  Any thoughts why?  A major study published in Vaccine this week highlights a complex tension in maternal health. While midwife-led care is consistently associated with superior neonatal outcomes and lower C-section rates (one step forward), the data show these children are significantly less likely to be up-to-date on vaccinations by age two (one step back). It would be good to see more recent data from the US, as this is from 2010-2015. Do you think it’s likely to have improved, stayed the same, or worsened? It’s a stark reminder that high-trust, personalized care models must be better integrated with broader public health goals to ensure long-term community immunity.

Source:Association of perinatal care provider type with routine vaccination‍ ‍

4. TrumpRx Expands: Bypassing the Traditional Pharmacy Payer The "TrumpRx" discounted drug platform added major reinforcements this week, including Jentadueto (Diabetes) and Striverdi Respimat (COPD). By offering deep direct-to-consumer discounts, the program is increasingly bypassing traditional PBM and insurance structures. For population health managers, this creates a dual reality: improved medication access for the uninsured, but a fragmented data landscape for health systems trying to track the total cost of care. Any thoughts on TrumpRx?  Big deal, limited impact, who knows?‍ ‍

Source:Boehringer Ingelheim Joins TrumpRx Platform with Key Chronic Meds‍ ‍

Bottom Line: We are getting better at the wins, record primary care matches, but we are still struggling with the integration of that care at the community level. What’s your take? Is the primary care "mismatch" our biggest hurdle for 2027?

Let me know your thoughts below or email me at info@accountablehealthllc.com. 👂💬